Immunologic Factor
Vaxcyte Advances 31-Valent Pneumococcal Vaccine to Phase 3 Trials Following Positive Phase 1/2 Results
Vaxcyte, VAX-31, Pneumococcal Vaccine, Phase 3 Trials, Invasive Pneumococcal Disease, Vaccine Development
Novavax’s Updated COVID-19 Vaccine Receives FDA Emergency Use Authorization
Novavax, COVID-19 vaccine, FDA, Emergency Use Authorization, protein-based vaccine, JN.1 variant
FDA Approves Emergent’s ACAM2000 Vaccine for Mpox Prevention, Pledges 50,000 Doses to Affected Regions
FDA approval, Emergent BioSolutions, ACAM2000 vaccine, mpox prevention, vaccine donation, global health response
UCLA Receives $120 Million Donation for Immunology Research and Vaccine Development
UCLA, immunology research, vaccine development, $120 million donation, Gary Michelson, Alya Michelson, California Institute for Immunology and Immunotherapy
Navigator Medicines Launches with $100 Million Series A Funding to Advance Autoimmune Disease Bispecific Antibody
Navigator Medicines, autoimmune disease, bispecific antibody, Series A funding, RA Capital Management, Forbion
Roche’s PiaSky Receives European Approval for Rare Blood Disorder Treatment
Roche, PiaSky, Crovalimab, Paroxysmal Nocturnal Hemoglobinuria (PNH), Rare Blood Disorder, European Approval
Cigna’s Express Scripts to Remove Humira from Preferred Lists in Favor of Cheaper Biosimilars
Cigna, Express Scripts, Humira, biosimilars, drug pricing, pharmaceutical industry
Regeneron Secures EU Approval for Lymphoma Treatment Ordspono Following FDA Rejection
Regeneron, EU approval, lymphoma, bispecific antibody, odronextamab, Ordspono, FDA rejection
Johnson & Johnson’s 340B Drug Discount Policy Change Rejected by HHS
Johnson & Johnson, 340B drug discount program, Stelara, Xarelto, HHS, HRSA, drug pricing, hospital payments
FDA Approves Updated Covid Vaccines for Fall Season: What You Need to Know
Covid-19 vaccines, FDA approval, updated vaccines, fall season, KP.2 strain, vaccination timing, immunity, side effects.